Company intelligence / Profile preview
Statera BioPharma
- Ownership
- Public · STAB
- Employees
- ~46
- Development stage
- Phase 3
Overview
Clinical-stage biopharma developing immune-restorative therapies through its AIMS platform, with multiple programs targeting autoimmune disorders, cancers and post-viral syndromes. Recent pipeline activity includes Phase III-ready Entolimod for radiation protection and STAT-201 advancing toward Phase III in pediatric Crohn's[1][4][5].
- Therapeutic areas
- OncologyImmunologyHematologyRheumatologyNeurologyInfectious Diseases
- Modalities
- ImmunotherapiesTLR agonists/antagonistsPeptide-based therapies
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Financials
- Market cap
- $14.3K
- Total revenue
- $670.5K
- Enterprise value
- $6.9M
Beyond the preview
Go deeper on Statera BioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Statera BioPharma.